Literature DB >> 1555838

Histologic grading of prostate cancer: a perspective.

D F Gleason1.   

Abstract

The wide-ranging biologic malignancy of prostate cancer is strongly correlated with its extensive and diverse morphologic appearances. Histologic grading is a valuable research tool that could and should be used more extensively and systematically in patient care. It can improve clinical staging, as outlined by Oesterling et al (J Urol 138: 92-98, 1987), during selection of patients for possible prostatectomy by helping to identify the optimal treatment. Some of the recurrent practical problems with grading (reproducibility, "undergrading" of biopsies, and "lumping" of grades) are discussed and recommendations are made. The newer technologically sophisticated but single-parameter tumor measurements are compared with one important advantage of histologic grading: the ability to encompass the entire low to high range of malignancy. The predictive success of grading suggests that prostate cancers have more or less fixed degrees of malignancy and growth rates (a hypothesis of "biologic determinism") rather than a steady increase in malignancy with time. Most of the observed facts can be interpreted on that basis, including the interrelations of tumor size, grade, and malignancy. The increasing age-adjusted incidence of diagnosed prostate cancer is attributed to new diagnostic tools and increased diagnostic zeal.

Entities:  

Mesh:

Year:  1992        PMID: 1555838     DOI: 10.1016/0046-8177(92)90108-f

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  175 in total

Review 1.  Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer.

Authors:  J Kurhanewicz; D B Vigneron; S J Nelson
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

2.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Oguz Akin; Changhong Yu; Kristen L Zakian; Kazuma Udo; Peter T Scardino; James Eastham; Michael W Kattan
Journal:  BJU Int       Date:  2011-09-20       Impact factor: 5.588

3.  Genomewide linkage analysis of familial prostate cancer in the Japanese population.

Authors:  Hiroshi Matsui; Kazuhiro Suzuki; Nobuaki Ohtake; Seiji Nakata; Toshiyuki Takeuchi; Hidetoshi Yamanaka; Ituro Inoue
Journal:  J Hum Genet       Date:  2003-12-10       Impact factor: 3.172

4.  Improving the reproducibility of the Gleason scores in small foci of prostate cancer--suggestion of diagnostic criteria for glandular fusion.

Authors:  B Helpap; G Kristiansen; M Beer; J Köllermann; U Oehler; A Pogrebniak; Ch Fellbaum
Journal:  Pathol Oncol Res       Date:  2011-12-17       Impact factor: 3.201

Review 5.  Nuclear morphometry, nucleomics and prostate cancer progression.

Authors:  Robert W Veltri; Christhunesa S Christudass; Sumit Isharwal
Journal:  Asian J Androl       Date:  2012-04-16       Impact factor: 3.285

6.  Should we abstain from Gleason score 2-4 in the diagnosis of prostate cancer? Results of a German multicentre study.

Authors:  Sabine Brookman-May; Matthias May; Wolf-Ferdinand Wieland; Steffen Lebentrau; Sven Gunia; Stefan Koch; Christian Gilfrich; Jan Roigas; Bernd Hoschke; Maximilian Burger
Journal:  World J Urol       Date:  2010-12-30       Impact factor: 4.226

7.  Optimization of ZD2 Peptide Targeted Gd(HP-DO3A) for Detection and Risk-Stratification of Prostate Cancer with MRI.

Authors:  Nadia R Ayat; Jing-Can Qin; Han Cheng; Sarah Roelle; Songqi Gao; Yajuan Li; Zheng-Rong Lu
Journal:  ACS Med Chem Lett       Date:  2018-06-06       Impact factor: 4.345

8.  Immunochemiluminescent detection of galectin-3 in tumoral tissue from prostate.

Authors:  Jorge Luiz Araújo-Filho; Mário Ribeiro Melo-Junior; Eduardo Isidoro Carneiro Beltrão; Luiza Rayanna Amorim de Lima; Consuelo Barreto Lins Antunes; Luiz Bezerra de Carvalho
Journal:  Int J Clin Exp Pathol       Date:  2013-08-15

9.  Expression and activity of matrix metalloproteinases-2 and -9 in serum, core needle biopsies and tissue specimens of prostate cancer patients.

Authors:  Christian G Sauer; Alexandra Kappeler; Monika Späth; Jens J Kaden; Maurice S Michel; Doris Mayer; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-16       Impact factor: 4.064

10.  In vivo tumor grading of prostate cancer using quantitative 111In-capromab pendetide SPECT/CT.

Authors:  Youngho Seo; Carina Mari Aparici; Matthew R Cooperberg; Badrinath R Konety; Randall A Hawkins
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.